TLR4 and TLR21 expression, MIF, IFN-β, MD-2, CD14 activation, and sIgA production in chickens administered with EFAL41 strain challenged with Campylobacter jejuni

. 2017 Mar ; 62 (2) : 89-97. [epub] 20161003

Jazyk angličtina Země Spojené státy americké Médium print-electronic

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/pmid27696326
Odkazy

PubMed 27696326
DOI 10.1007/s12223-016-0475-6
PII: 10.1007/s12223-016-0475-6
Knihovny.cz E-zdroje

The protective effect of Enterococcus faecium EFAL41 on chicken's caecum in relation to the TLR (TLR4 and TLR21) activation and production of luminal IgA challenged with Campylobacter jejuni CCM6191 was assessed. The activation of MIF, IFN-β, MD-2 and CD14 was followed-up after bacterial infection. Day-old chicks (40) were divided into four groups (n = 10): control (C), E. faecium AL41 (EFAL41), C. jejuni (CJ) and combined E. faecium AL41+C. jejuni (EFAL41+CJ). Relative mRNA expression of TLR4, TLR21 and CD14 was upregulated in the probiotic strain and infected (combined) group on day 4 and 7 post infection (p.i.). The caecal relative MD-2 mRNA expression was upregulated on day 4 p.i. in the EFAL41+CJ and CJ groups. MIF and IFN-β reached the highest levels in the combined groups on day 7 p.i. The concentration of the sIgA in intestinal flush was upregulated in EFAL41+CJ group on day 4 p.i. The results demonstrated that E. faecium EFAL41 probiotic strain can modulate the TLRs expression and modify the activation of MIF, IFN-β, MD-2 and CD14 molecules in the chickens caecum challenged with C. jejuni CCM 6191. The counts of EFAL41 were sufficient and high, similarly the counts of enterococci in both, caecum and faeces but without reduction of Campylobacter counts.

Zobrazit více v PubMed

Gastroenterology. 2008 Aug;135(2):529-38 PubMed

Infect Immun. 2010 Mar;78(3):1229-38 PubMed

Infect Immun. 2008 Oct;76(10):4498-508 PubMed

Cell Microbiol. 2011 Nov;13(11):1668-82 PubMed

Immunol Rev. 1999 Aug;170:197-222 PubMed

Nat Immunol. 2001 Dec;2(12):1093-4 PubMed

Mucosal Immunol. 2012 Nov;5(6):623-34 PubMed

Benef Microbes. 2012 Sep;3(3):205-10 PubMed

J Clin Microbiol. 2011 Aug;49(8):2868-73 PubMed

J Exp Med. 1999 Jun 7;189(11):1777-82 PubMed

Nat Rev Immunol. 2004 Jun;4(6):478-85 PubMed

J Immunol. 2010 Jul 1;185(1):460-7 PubMed

Int Immunol. 2001 Dec;13(12):1595-9 PubMed

Immunogenetics. 2009 Feb;61(2):101-10 PubMed

Vet Res. 2011 May 18;42:64 PubMed

Curr Opin Infect Dis. 2007 Oct;20(5):514-8 PubMed

Nat Immunol. 2002 Jul;3(7):667-72 PubMed

Avian Dis. 2006 Mar;50(1):55-8 PubMed

MBio. 2013 Jun 11;4(3):e00609-12 PubMed

Mol Immunol. 2009 Sep;46(15):3163-70 PubMed

Microbiology. 2008 Dec;154(Pt 12):3835-47 PubMed

Poult Sci. 2004 Apr;83(4):544-9 PubMed

Res Vet Sci. 2015 Jun;100:75-9 PubMed

J Immunol. 2007 Mar 1;178(5):3126-33 PubMed

Nature. 2001 Dec 20-27;414(6866):920-4 PubMed

BMC Microbiol. 2008 Jun 27;8:107 PubMed

Int J Food Microbiol. 2011 Dec 2;151(2):125-40 PubMed

Anim Genet. 2011 Oct;42(5):491-500 PubMed

Infect Immun. 2009 Jun;77(6):2499-507 PubMed

Vet Immunol Immunopathol. 2008 Apr 15;122(3-4):312-7 PubMed

J Clin Microbiol. 1997 Nov;35(11):2966-8 PubMed

Probiotics Antimicrob Proteins. 2012 Dec;4(4):243-9 PubMed

Poult Sci. 1999 Nov;78(11):1510-7 PubMed

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace